Active Filter(s):
Details:
ValiRx had entered into an agreement with Kalos Therapeutics, whereby ValiRx would perform a range of preclinical evaluation experiments to determine whether to enter a full licensing agreement for KTH222.
Lead Product(s): KTH222
Therapeutic Area: Oncology Product Name: KTH222
Highest Development Status: Preclinical Product Type: Peptide
Recipient: Kalos Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination May 27, 2021
Details:
ValiRx will benefit from Physiomics' expertise in modelling the effects of prostate cancer care, as well as the latest version of its Virtual TumourTM technology, which will be used to extract useful information from the additional data provided by the VAL201 clinical trial.
Lead Product(s): VAL201
Therapeutic Area: Oncology Product Name: VAL201
Highest Development Status: Phase I/ Phase II Product Type: Peptide
Recipient: Physiomics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 17, 2021
Details:
Under the terms of the agreement, ValiRx has the right to perform a defined series of preclinical, cell-based assays to consider the benefit of using KTH222 in combination with standard of care treatment, Paclitaxel.
Lead Product(s): KTH222
Therapeutic Area: Oncology Product Name: KTH222
Highest Development Status: Preclinical Product Type: Peptide
Recipient: Kalos Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 10, 2020
Details:
Agreement signed with the company will see VAL301 evaluated for the purpose of contemplating a potential future license for the treatment of endometriosis.
Lead Product(s): VAL301
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 01, 2020